Status:
COMPLETED
Bioequivalence Study of Sotalol, Tablets, 160 mg (Pharmtechnology LLC, Belarus), and Sotalex ®, Tablets, 160 mg (Bristol-Myers Squibb GmbH & Co. KGaA, Germany), in Healthy Volunteers Under Fasting Conditions
Lead Sponsor:
Pharmtechnology LLC
Collaborating Sponsors:
National Anti-Doping Labaratory
Conditions:
Bioequivalence
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This is an open-label, randomized, single-center, single-dose, two-treatment, two-sequence, two-period, crossover, comparative study, where each subject was randomly assigned to the reference or the t...
Detailed Description
The objective of this study is to establish if two formulations of sotalol are bioequivalent. The test formulation is Sotalol Tablets, 160 mg (Pharmtechnology LLC, Belarus). The reference formulation ...
Eligibility Criteria
Inclusion
- Caucasian men or women aged between 18 to 55 years
- Body mass index 18.5-30 kg/m²
- Subjects who have no signs of disease during the screening, and whose screening is conducted within 21 days after the registration in the trial
- Subjects whose laboratory blood and urine values are within the normal range orof deviations are considered by researchers to be clinically insignificant
- Non-smokers or ex-smokers (defined as completely quitting smoking for at least three months prior to being included in the test)
- No known history of alcohol abuse
- No known history of abuse of drugs (benzodiazepines, opioids, cocaine, barbiturates, amphetamine, etc.)
- Willingness to comply with the protocol requirements regarding the restriction of the consumption of products containing xanthine (coffee, tea, chocolate, cola, etc.) for at least 48 hours and products containing tobacco, alcohol-containing products and beverages, grapefruit and/or its juice, food containing poppy at least 72 hours prior taking the investigational medicinal products and over the course of the study, as well as requirements regarding the intake of food, fluids and physical activity imposed by the study
- Healthy subject according to medical history, physical examination and assessment of basic vital signs
- No significant abnormalities on 12-lead ECG
- No significant abnormalities on the chest x-ray obtained within 12 months prior the start of the study
- Consent of women of childbearing age and male participants to use medically confirmed barrier methods of contraception (from the date of screening to the completion of the study), or surgical sterilization in history, or women in postmenopause (at least 24 months) or hysterectomy in history . If women use hormonal contraceptives,they should stop them at least 60 days prior the planned beginning of the study
- The subject's voluntary willingness to provide written informed consent
- The ability, at disceretion of the researcher, to follow all the requirements of the protocol
- The ability, at judgment of the researcher, to follow all the requirements of the protocol
Exclusion
- Known history of allergy
- Known contraindications to the use of investigational products or hypersensitivity to the active substance or components of drugs
- Use of drugs with enzymatic-modifying activity, within 28 days prior the beginning of the study
- Use any over-the-counter or prescription drugs (including vitamins, minerals, herbal remedies, and dietary supplements) within 14 days prior the administration of investigational products and over the course of the study
- Intense physical exercises within 24 hours prior to the administration of investigational products
- Any medical or surgical interventions that can disrupt the function of the hematopoietic system, the gastrointestinal tract (with the exception of appendectomy), the liver, urinary system and other body systems
- Any chronic diseases or conditions of the urinary, cardiovascular, neuroendocrine, immune, central nervous systems, hematopoietic system, gastrointestinal tract, liver, organs of vision and other systems of the body and diabetes in medical history, mental illness in an active phase or the history
- The presence of any hereditary disease
- Participation in any clinical trials within 90 days prior the beginning of the current clincial study
- Oncological diseaes in medical history
- Any blood donation within 90 days prior the beginning of the current clincial study
- Acute infectious diseases within 28 days prior the beginning of the current clincial study as well as positive testing for HIV, hepatitis B and C, and syphilis
- Positive test for alcohol
- Positive urinary screen test for drugs of abuse
- Swallowing problems in mediical history
- Positive urinary pregnancy test
- Breast-feeding
- Known history of venous access difficulties
- Vegetarian diet
- Sitting systolic blood pressure \< 110 mm Hg or \> 140 mm Hg and/or sitting diastolic blood pressure \< 70 mm Hg or \> 90 mm Hg.Heart rate \<50 or \>100 beats per minute at screening check-in
- Values of the standard laboratory and instrumental tests outside of normal limits and are judged as clinically significant by investigators or require additional examination and interpretation.
Key Trial Info
Start Date :
January 9 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 11 2019
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT03799536
Start Date
January 9 2019
End Date
February 11 2019
Last Update
June 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Anti-Doping Laboratory
Settl.Lesnoy, Minsk Oblast, Belarus, 223040